Roche Holding ( ) - 株価, ニュースと分析SWX:ROG

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

ROG 株式概要

ロシュ・ホールディングAGは、欧州、北米、中南米、アジア、アフリカ、オーストラリア、オセアニアで医薬品および診断薬事業を展開しています。

ROG ファンダメンタル分析
スノーフレーク・スコア
評価	5/6
将来の成長	3/6
過去の実績	4/6
財務の健全性	4/6
配当金	5/6

報酬

当社が推定した公正価値より63.5%で取引されている

収益は年間8.54%増加すると予測されています

3.87%の安定した配当金を支払う

同業他社や業界と比較して、良好な取引価格

リスク分析

多額の負債を抱えている

Roche Holding AG 競合他社

Novartis

SWX:NOVN

CHF191.8b

Sandoz Group

SWX:SDZ

CHF14.1b

Dottikon ES Holding

SWX:DESN

CHF3.6b

AstraZeneca

LSE:AZN

UK£193.3b

価格と性能

の歴代最高値、変動、値下がりまとめRoche Holding
過去の株価
現在の株価	CHF252.80
52週高値	CHF278.60
52週安値	CHF212.90
ベータ	0.16
11ヶ月の変化	9.01%
3ヶ月変化	12.21%
1年変化	-8.57%
33年間の変化	-26.68%
5年間の変化	-7.96%
IPOからの変化	868.58%

Recent updates

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Apr 17

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 06

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 09

株主還元

	ROG	CH Pharmaceuticals	CH 市場
7D	2.1%	0.6%	-0.09%
1Y	-8.6%	19.9%	4.0%

業界別リターン: ROG過去 1 年間で19.2 % の収益を上げたSwiss Pharmaceuticals業界を下回りました。

リターン対市場: ROGは、過去 1 年間で4.1 % のリターンを上げたSwiss市場を下回りました。

価格変動

Is ROG's price volatile compared to industry and market?
ROG volatility
ROG Average Weekly Movement	2.6%
Pharmaceuticals Industry Average Movement	3.6%
Market Average Movement	3.4%
10% most volatile stocks in CH Market	6.0%
10% least volatile stocks in CH Market	1.9%

安定した株価: ROG過去 3 か月間に大きな価格変動はありませんでした。

時間の経過による変動: ROGの週次ボラティリティ ( 3% ) は過去 1 年間安定しています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
1896	103,605	Thomas Schinecker	www.roche.com

ロシュ・ホールディングAGは、欧州、北米、中南米、アジア、アフリカ、オーストラリア、オセアニアで医薬品および診断薬事業を展開している。貧血、血液・固形がん、皮膚科、血友病、炎症・自己免疫疾患、神経疾患、眼科、呼吸器疾患、移植の治療分野で医薬品を提供している。また、様々な治療分野向けの製品開発も行っている。さらに、がん、糖尿病、Covid-19、肝炎、ヒトパピローマウイルスなど様々な疾患の診断のための体外検査、診断機器、デジタルヘルスソリューションを提供している。ロシュ・ホールディングAGは1896年に設立され、スイスのバーゼルに本社を置いている。

Roche Holding AG 基礎のまとめ

Roche Holding の収益と売上を時価総額と比較するとどうか。
ROG 基礎統計学
時価総額	CHF203.98b
収益（TTM）	CHF11.50b
売上高(TTM)	CHF60.44b

17.5x

PER（株価収益率

3.3x

P/Sレシオ

ROG は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
ROG 損益計算書（TTM）
収益	CHF60.44b
売上原価	CHF15.60b
売上総利益	CHF44.84b
その他の費用	CHF33.35b
収益	CHF11.50b

直近の収益報告

Dec 31, 2023

次回決算日

該当なし

一株当たり利益（EPS）	14.42
グロス・マージン	74.19%
純利益率	19.02%
有利子負債／自己資本比率	88.0%

ROG の長期的なパフォーマンスは？

過去の実績と比較を見る

配当金

3.8%

現在の配当利回り

67%

配当性向

ROG 株式概要

報酬

リスク分析

Roche Holding AG 競合他社

SWX:NOVN

CHF191.8b

SWX:SDZ

CHF14.1b

SWX:DESN

CHF3.6b

LSE:AZN

UK£193.3b

価格と性能

最新ニュース

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)

Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity

Recent updates

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)

Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity

Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Upcoming dividend of CHF9.60 per share

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Roche Holding's (VTX:ROG) Soft Earnings Are Actually Better Than They Appear

Full year 2023 earnings: EPS and revenues miss analyst expectations

Dividend increased to CHF9.60

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Roche Holding AG Proposes Dividend

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Market Cool On Roche Holding AG's (VTX:ROG) Earnings

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition

Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A

Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion.

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List

Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types

Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration

Roche Announces EMBARK Trial in Duchenne Muscular Dystrophy

United States Food and Drug Administration Approves Roche's Vabysmo for the Treatment of Retinal Veinocclusion (RVO)

Roche Holding AG Confirms Outlook for 2023

Roche Announces Roche IL-6 Is the First Immunoassay Approved to Aid Sepsis Diagnosis in Newborns

Roche Announces New Clinical and Real-World Data for Orevus (Ocrelizumab)

Roche Holding AG Announces Late-Breaking Data from the Phase III Ocarina III Study as an Investigational Twice-Yearly, 10-Minute Subcutaneous Injection on Pharmacokinetic, Biomarker, and Mri Measures in Patients with Relapsing or Primary Progressive Multiple Sclerosis

Roche Presents Positive Results from the Primary Analysis of the Ongoing Rainbowfish Study Assessing the Efficacy and Safety of Evrysdi

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

Roche’S Alecensa Delivers Unprecedented Phase III Results for People with ALK-positive early-stage lung cancer

Roche Holding AG Tecentriq Becomes the First Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy Available to Patients in Great Britain, Reducing Treatment Time to Just Minutes

Is Roche Holding (VTX:ROG) A Risky Investment?

Roche Provides Update on Phase III Skyscraper-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer

New minor risk - Earnings quality

Roche Holding AG Confirms Earnings Guidance for the Year 2023

Roche Announces New Clinical and Real-World Data for Vabysmo at ASRS Reveal Improved Outcomes for People with Two Leading Causes of Vision Loss

Roivant Sciences Reportedly Near Deal to Sell Stomach Drug to Roche for over $7 Billion

Roche Announces Positive Phase III Results for Roche’s OCREVUS (ocrelizumab) Twice a Year, 10-minute Subcutaneous Injection in Patients with Multiple Sclerosis

European Commission Approves Roche Holding AG's Fixed-Term Columvi (Glofitamab) for People with Relapsed or Refractory Diffuse Large B-Cell L-Cell Lymphoma

Roche Receives FDA Clearance for Additional Alzheimer's Disease Cerebrospinal Fluid Assays, Supporting Timely Diagnosis and Treatment Decision-Making